Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial

Pembrolizumab With or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

Early Disease Recurrence Following Post-operative HPV ctDNA Directed Active Surveillance in Oropharyngeal Carcinoma – Outcomes of a Prospective Pilot Study

Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and neck (LASCCHN).

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker Correlatives

Early outcomes for a single-arm phase I/II trial of Selective Avoidance of nodal VolumEs at minimal Risk (SAVER) in the contralateral N0 neck of patients with p16-positive oropharynx cancer

Enfortumab vedotin (EV) in the previously treated advanced head and neck cancer (HNC) cohort of EV-202

Subgroup analysis of the benefit of avasopasem manganese on the incidence, severity, duration and onset of severe oral mucositis in ROMAN Phase 3 Trial

Efficacy and Safety of Surufatinib for Recurrent or Metastatic Malignant Salivary Gland Tumors: An Open-Label, Single-Arm, Phase II Study

A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3rd line and in combination with pembrolizumab in 1st line recurrent/metastatic (R/M) HPV16+ head and neck cancer patients.

Patient-Reported Outcomes and Financial Toxicity in Head and Neck Cancer (PaRTNer): Longitudinal Assessment of Financial Toxicity and Coping Mechanisms

Safety and Toxicity of Iopofosine I-131 with External Beam Radiation Therapy (EBRT) in Recurrent or Metastatic Head and Neck Cancer (HNC): Results of a Phase 1 Study

First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial

Safety and Tolerability of Magrolimab Combination Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)

FDG-PET-based Selective De-escalation of Radiotherapy for HPV-Related Oropharynx Cancer: Results from a Phase II Trial